Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 4, 2014, Pages 596-604

  Mhlanga, Joyce C ^a   Durand, Daniel ^a   Tsai, Hua Ling ^a   Durand, Christine M ^a   Leal, Jeffrey P ^a   Wang, Hao ^a   Moore, Richard ^a   Wahl, Richard L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Lymphadenopathy; Lymphoma; PET CT; TLG

Indexed keywords

FLUORODEOXYGLUCOSE F 18; VIRUS RNA; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSTITUTIONAL REVIEW; LARGE CELL LYMPHOMA; LEAN BODY WEIGHT; LYMPHADENOPATHY; MALE; MIDDLE AGED; PET-CT SCANNER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REACTIVE ADENOPATHY; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR VOLUME; VIRUS LOAD; B CELL LYMPHOMA; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; LYMPH NODE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897026861     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2671-9     Document Type: Article

References (29)

1. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol. 2011;6:223-48.
2. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non- Hodgkin lymphoma. Lancet. 1991;337:805-9.
3. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis. 2006;19:14-9. (Pubitemid 43032434)
4. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-62.
5. Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003;362:959-61. (Pubitemid 37159292)
6. Liu Y. Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med. 2011;25:536-46.
7. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics. 2005;25:1357-68. (Pubitemid 41695350)
8. Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. J Nucl Med. 2008;49:1980-5.
9. Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. FDG-PET in fever of unknown origin. Semin Nucl Med. 2013;43:333-9.
10. Bental M, Deutsch C. Metabolic changes in activated T cells: an NMR study of human peripheral blood lymphocytes. Magn Reson Med. 1993;29:317-26. (Pubitemid 23114497)
11. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-9. (Pubitemid 26398421)
12. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-8. (Pubitemid 350002965)
13. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575-83. (Pubitemid 27443958)
14. Goudarzi B, Jacene HA, Wahl RL. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010;17(9):1175-85.
15. Lodge MA, Chaudhry MA, Udall DN, Wahl RL. Characterization of a perirectal artifact in 18F-FDG PET/CT. J Nucl Med. 2010;51(10):1501-6.
16. Liu Y. Concurrent FDG avid nasopharyngeal lesion and generalized lymphadenopathy on PET-CT imaging is indicative of lymphoma in patients with HIV infection. AIDS Res Treat. 2012; 2012:764291.
17. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50.
18. Frisch M, Biggar RJ, Engels EA, Goedert JJ, AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736-45. (Pubitemid 32259908)
19. Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIVAIDS. 2009;4:459-66.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74. (Pubitemid 8054849)
21. Scadden DT. AIDS-related malignancies. Annu Rev Med. 2003;54:285-303. (Pubitemid 37386398)
22. Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477-82.
23. Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH. Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet. 2003;362:945-50. (Pubitemid 37168049)
24. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430-8. (Pubitemid 46207018)
25. Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIVinfection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20:985-93.
26. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am. 2003;17:673-96. (Pubitemid 36807592)
27. Goshen E, Davidson T, Avigdor A, Zwas TS, Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med. 2008;33:610-4.
28. Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. 2009;36:640-7.
29. Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784-8. (Pubitemid 47618557)